Intra-Cellular Therapies, Inc.
ITCI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ITCI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2024.
Tracking 3 pipeline candidates · 20 clinical trials · 1 FDA decision for Intra-Cellular Therapies, Inc..
Run Intra-Cellular Therapies, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Intra-Cellular Therapies, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
13.9 months
D/E 0.19
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Intra-Cellular Therapies, Inc.'s lead drug candidate?
Intra-Cellular Therapies, Inc.'s most advanced tracked candidate is Caplyta (Approved) for Schizophrenia (adults); Bipolar depression (adults).
Who is the CEO of Intra-Cellular Therapies, Inc.?
Chief Executive Officer is the chief executive officer of Intra-Cellular Therapies, Inc. (ITCI).
What therapeutic areas does Intra-Cellular Therapies, Inc. focus on?
Intra-Cellular Therapies, Inc. develops therapies across Oncology, Neurology, Immunology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.